About: Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview
Creator	Blijlevens, Nma De Pauw, B Donnelly, J
source	PMC
abstract	Mucositis is an inevitable side-effect of the conditioning regimens used for haematopoietic stem cell transplantation. The condition is better referred to as mucosal barrier injury (MBI) since it is primarily the result of toxicity and is a complex and dynamic pathobiological process manifested not only in the mouth but also throughout the entire digestive tract. A model has been proposed for oral MBI and consists of four phases, namely inflammatory, epithelial, ulcerative and healing phases. A variety of factors are involved in causing and modulating MBI including the nature of the conditioning regimen, the elaboration of pro-inflammatory and other cytokines, translocation of the resident microflora and their products, for example, endotoxins across the mucosal barrier, exposure to antimicrobial agents and whether or not the haematopoietic stem cell graft is from a donor. Neutropenic typhlitis is the most severe gastrointestinal manifestation of MBI, but it also influences the occurrence of other major transplant-related complications including acute GVHD, veno-occlusive disease and systemic infections. The pathobiology, clinical counterparts and the means of measuring MBI are discussed together with potential approaches for prevention, amelioration and, perhaps, even cure. Bone Marrow Transplantation (2000) 25, 1269–1278.
has issue date	2000-06-19(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1702447
bibo:pmid	10871732
has license	no-cc
sha1sum (hex)	09a1199fdaef1f2e2742272ac3708df4f4dff0eb
schema:url	https://doi.org/10.1038/sj.bmt.1702447
resource representing a document's title	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview
has PubMed Central identifier	PMC7091624
has PubMed identifier	10871732
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:09a1199fdaef1f2e2742272ac3708df4f4dff0eb#body_text
is schema:about of	named entity 'prevention' named entity 'digestive tract' named entity 'nature' named entity 'condition' named entity 'BETTER' named entity 'EPITHELIAL' named entity 'POTENTIAL' named entity 'BUT' named entity 'MODULATING' named entity 'APPROACHES' named entity 'RESIDENT' named entity 'CONSEQUENCES' named entity 'inflammatory' named entity 'injury' named entity 'agents' named entity 'gastrointestinal' named entity 'severe' named entity 'resident' named entity 'epithelial' named entity 'toxicity' named entity 'pathobiology' named entity 'translocation' named entity 'veno-occlusive disease' named entity 'microflora' named entity 'haematopoietic stem cell transplantation' named entity 'pathobiological' named entity 'conditioning regimen' named entity 'graft' named entity 'haematological malignancy' named entity 'intensive treatment' named entity 'intestinal microflora' named entity 'neutropenia' named entity 'oral hygiene' named entity 'bacterial translocation' named entity 'SATs' named entity 'microflora' named entity 'inflammation' named entity 'microbes' named entity 'antimicrobial agents' named entity 'nutritional status' named entity 'disaccharides' named entity 'toxicity' named entity 'monoclonal antibodies' named entity 'neutropenia' named entity 'fibroblast growth factor' named entity 'irradiation' named entity 'biologically active' named entity 'mucus' named entity 'enzyme activity' named entity 'cytarabine' named entity 'GALT' named entity 'D-xylose' named entity 'morbidity' named entity 'PEG' named entity 'haematopoietic stem cell transplant' named entity 'mucosal surface' named entity 'Epithelial cells' named entity 'pro-inflammatory cytokine' named entity 'HLA' named entity 'bacterial translocation' named entity 'blood loss' named entity 'antigens' named entity 'monoclonal antibody' named entity 'chemotherapy' named entity 'fever' named entity 'Infection' named entity 'saliva' named entity 'streptococci' named entity 'brush border' named entity 'malabsorption' named entity 'cytotoxic drugs' named entity 'rapidly dividing cells' named entity 'Pseudomonas aeruginosa' named entity 'diarrhoea' named entity 'pathobiological' named entity 'low-grade' named entity 'mucosal' named entity 'stomach' named entity 'naturally occurring'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software